We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.78%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.01B
AUM Growth
+$119M
Cap. Flow
-$210M
Cap. Flow %
-2.99%
Top 10 Hldgs %
36.63%
Holding
168
New
9
Increased
52
Reduced
52
Closed
12

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$40.7M
2
LLY icon
Eli Lilly
LLY
+$35.4M
3
MRK icon
Merck
MRK
+$34M
4
HUM icon
Humana
HUM
+$29.6M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$29.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$57.6M
2
APLS
Apellis Pharmaceuticals
APLS
+$51M
3
BSX icon
Boston Scientific
BSX
+$40.6M
4
HCA icon
HCA Healthcare
HCA
+$39.8M
5
ISRG icon
Intuitive Surgical
ISRG
+$38.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Industrials 0.87%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
51
Elevance Health
ELV
$80.9B
$45.5M 0.65%
102,453
+9,483
+10% +$4.37M
LLY icon
52
Eli Lilly
LLY
$1.05T
$44.6M 0.64%
95,155
+84,391
+784% +$35.4M
DHR icon
53
Danaher
DHR
$144B
$44.1M 0.63%
207,224
-173,353
-46% -$36.7M
SILK
54
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$44.1M 0.63%
1,356,763
+287,024
+27% +$10.5M
ZBH icon
55
Zimmer Biomet
ZBH
$17.6B
$41.5M 0.59%
284,835
+19,565
+7% +$2.66M
AXSM icon
56
Axsome Therapeutics
AXSM
$11.8B
$41.3M 0.59%
574,363
+133,013
+30% +$9.81M
BDTX icon
57
Black Diamond Therapeutics
BDTX
$103M
$41.1M 0.59%
8,135,839
+2,740,000
+51% +$5.6M
GMED icon
58
Globus Medical
GMED
$10.5B
$38.6M 0.55%
647,645
– –
ATRC icon
59
AtriCure
ATRC
$1.77B
$37M 0.53%
748,613
+101,391
+16% +$4.67M
IQV icon
60
IQVIA
IQV
$34.4B
$36.4M 0.52%
162,120
-10,358
-6% -$2.08M
JAZZ icon
61
Jazz Pharmaceuticals
JAZZ
$15.5B
$35.8M 0.51%
288,779
-281,078
-49% -$37.8M
MRK icon
62
Merck
MRK
$315B
$35.4M 0.5%
306,694
+299,619
+4,235% +$34M
COO icon
63
Cooper Companies
COO
$14B
$33.2M 0.47%
346,268
+21,016
+6% +$1.97M
CDNA icon
64
CareDx
CDNA
$2.05B
$31.6M 0.45%
3,716,477
+277,386
+8% +$2.31M
BMRN icon
65
BioMarin Pharmaceuticals
BMRN
$11.5B
$31.3M 0.45%
360,604
+312,159
+644% +$29.4M
PRVA icon
66
Privia Health
PRVA
$3.39B
$29.3M 0.42%
1,122,644
+120,000
+12% +$3.17M
PRCT icon
67
Procept Biorobotics
PRCT
$1.09B
$26.2M 0.37%
741,517
– –
HOLX
68
DELISTED
Hologic
HOLX
$23.5M 0.34%
290,136
– –
FATE icon
69
Fate Therapeutics
FATE
$324M
$23.1M 0.33%
4,855,779
– –
SRPT icon
70
Sarepta Therapeutics
SRPT
$1.82B
$22.9M 0.33%
200,220
-446,394
-69% -$57.6M
BEAM icon
71
Beam Therapeutics
BEAM
$2.83B
$22.2M 0.32%
695,421
– –
HCM icon
72
HUTCHMED
HCM
$1.86B
$21.7M 0.31%
1,805,583
-21,387
-1% -$292K
OMCL icon
73
Omnicell
OMCL
$2.09B
$21.6M 0.31%
293,345
-170,022
-37% -$11.5M
RMD icon
74
ResMed
RMD
$28.9B
$21.5M 0.31%
98,275
– –
AMED
75
DELISTED
Amedisys
AMED
$21.4M 0.31%
234,318
-308,298
-57% -$25.3M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2023 Portfolio in Review

As of Q2 2023, Bellevue Group held 168 positions worth $7.01B, up 1.7% from $6.89B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group's Q2 2023 filing shows 9 new, 52 increased, 52 reduced and 12 closed positions. Its largest new stake was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M. The largest sale was Sarepta Therapeutics, an estimated $57.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2023 buy was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M.
  • Bellevue Group added most to Evolent Health in Q2 2023, an estimated $40.7M increase.
  • Bellevue Group's biggest Q2 2023 reduction was Sarepta Therapeutics, cutting an estimated $57.6M.
  • Bellevue Group fully exited Pfizer in Q2 2023, selling an estimated $30.2M.
  • Bellevue Group's ten largest holdings make up 37% of its $7.01B portfolio in Q2 2023.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2023.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $7.01B.

Based on Bellevue Group's 13F filing for Q2 2023, filed 14 Aug 2023.